Compare UIS & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UIS | LENZ |
|---|---|---|
| Founded | 1942 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.2M | 198.8M |
| IPO Year | 1994 | 2021 |
| Metric | UIS | LENZ |
|---|---|---|
| Price | $3.53 | $5.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.67 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 1.1M | 556.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,950,100,000.00 | $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | $2.60 | $197.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $6.29 |
| 52 Week High | $4.98 | $50.19 |
| Indicator | UIS | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 29.43 |
| Support Level | $3.51 | N/A |
| Resistance Level | $4.06 | $10.42 |
| Average True Range (ATR) | 0.30 | 0.43 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 3.64 | 3.26 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.